Memorial Hospital Research Laboratories

The Luke Pike Lab

Share
Back to top

Research

Luke Pike
Luke Pike, MD, DPhil

The Luke Pike Lab seeks to understand the unique biology of brain metastasis (BM) to improve outcomes for patients afflicted with various solid tumors. BM is exceptionally common, with an estimated 400,000 patients diagnosed yearly in the U.S. The mechanisms by which cancer cells spread to and survive in the brain are poorly understood. The standard treatment for BM has been radiation therapy with or without surgical resection, as most drug therapies are ineffective against BM. New drugs, such as immune checkpoint or targeted inhibitors, have shown promising activity against BM, but our understanding of why they often fail in the brain is incomplete. The Pike Lab uses cutting-edge molecular techniques to understand tumor tropism for the brain and to identify features of human BM that might lead to drug or radiation resistance and the survival of cancer cells in the brain tumor microenvironment.

Luke Pike Lab group outing

Publications

Skakodub A, Tringale KR, Walch HS, Vasudevan H, Eichholz J, Kelly D, Moss NS, Yu KKH, Li BT, Mueller B, Yang JT, Beal K, Imber BS, Gomez DR, Schultz N, Pike LRG. Genomic analysis and clinical correlations of non-small cell lung cancer (NSCLC) brain metastasis (BM). Journal of Clinical Oncology 2022 40:16_suppl, 2008-2008.

Hwang WL*, Pike LRG*, Royce TJ, Mahal BA, Loeffler JS. Safety of combining radiotherapy with immune-checkpoint inhibition. Nat Rev Clin Oncol. 2018 Aug;15(8):477-494. doi: 10.1038/s41571-018-0046-7. Review. *Co-first authors.

Pike LRG, Bang A, Ott P, Balboni T, Taylor A, Catalano P, Rawal B, Spektor A, Krishnan M, Cagney D, Alexander B, Aizer AA, Buchbinder E, Awad M, Gandhi L, Hodi FS, Schoenfeld JD. Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation. Radiother Oncol. 2017 Jul;124(1):98-103. doi: 10.1016/j.radonc.2017.06.006. Epub 2017 Jun 26.

View All Publications

People

Luke Pike

Luke Pike, MD, DPhil

  • Physician-scientist Luke R.G. Pike studies the mechanistic underpinnings of brain metastasis and seeks to identify translational correlates with outcomes following local or systemic therapy.
  • DPhil/PhD, Medical Oncology, University of Oxford
  • MD, Yale School of Medicine
[email protected]
Email Address
View physician profile
Physician profile

Members

Kevin Boehm
Kevin M. Boehm

Resident Physician, Memorial Sloan Kettering Cancer Center, New York, NY

Gustav Cederquist

Memorial Sloan Kettering RO PGY3

Claire Cooper

Intern

Luke del Balzo
Luke del Balzo

Medical College of Georgia MS3

Jordan Eichholz
Jordan Eichholz

Project Coordinator

Benjamin Gaeta
Benjamin Gaeta

Cornell MS3

Chengcheng Gui
Chengcheng Gui

Memorial Sloan Kettering RO PGY3

Ishaani Khatri
Ishaani Khatri

Brown MS2

Rahul Kumar

Undergraduate, University of Miami

Emily Lebow
Emily Lebow

Memorial Sloan Kettering RO PGY5

Jennifer Ma
Jennifer Ma

Memorial Sloan Kettering RO PGY4

Amandeep R. Mahal

Harvard Radiation Oncology Program, PGY3

Emily Miao
Emily Miao

Albert Einstein MS3

Kirin Mueller

Yale Undergrad

Anna Skakodub
Anna Skakodub

Pennsylvania State College of Medicine MS3

Kathryn Tringale
Kathryn Tringale

Memorial Sloan Kettering RO PGY5

Ross Weber

Memorial Sloan Kettering PGY1

Lab Alumni
Alexi Dreyfuss

Memorial Sloan Kettering RO PGY3

Lab Affiliations

Achievements

  • Alexander Graham Bell PhD Scholarship (2009)
  • The Rhodes Scholarship (2007)

Get in Touch

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Luke Pike discloses the following relationships and financial interests:

  • Clovis Oncology
    Equity
  • Monograph Capital Advisors, L.P.
    Professional Services and Activities
  • Monte Rosa Therapeutics, Inc.
    Professional Services and Activities
  • Turnstone Biologics Corp.
    Professional Services and Activities

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures